Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19114812 | 0.83 | DYRK1A (0.46) | DYRK1AGSK3BNFATC1GPR84CDK2 | |
| SCHEMBL12491378 | 0.82 | DYRK1A (0.49) | DYRK1AGSK3BNFATC1GPR84CDK2 | |
| SCHEMBL2611046 | 0.78 | DYRK1A (0.51) | DYRK1AGSK3BNFATC1GPR84CDK2 | |
| SCHEMBL14663984 | 0.78 | DYRK1A (0.45) | DYRK1AGSK3BNFATC1GPR84CDK2 | |
| SCHEMBL17242302 | 0.77 | GPR84 (0.69) | GPR84HTR2AFFAR1MAPT | |
| SCHEMBL22430402 | 0.76 | DYRK1A (0.49) | DYRK1AGSK3BNFATC1GPR84CDK2 | |
| SCHEMBL27898298 | 0.75 | DYRK1A (0.42) | DYRK1AGSK3BNFATC1CDK2DYRK1B | |
| SCHEMBL27764322 | 0.75 | DYRK1A (0.42) | DYRK1AGSK3BNFATC1CDK2DYRK1B | |
| SCHEMBL4266740 | 0.74 | MAPT (0.48) | DYRK1AGSK3BNFATC1GPR84CDK2 | |
| SCHEMBL14827561 | 0.73 | DYRK1A (0.46) | DYRK1AGSK3BNFATC1GPR84CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | DYRK1A 4352/4885GSK3B 1350/4885NFATC1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.